What does Natera’s leadership change mean for Signatera and precision oncology?
Natera names Solomon Moshkevich CEO as oncology testing rises 61% and revenue reaches $794 million. Examine the growth and execution risks.
Medical Devices & Diagnostics
Pharma & Biotech
TransCode Therapeutics has advanced TTX-MC138 into Phase 2a, so why is it exploring a sale or strategic partnership?
TransCode appoints Tungsten Advisors to explore TTX-MC138 licensing and sale options as its ctDNA-positive colorectal cancer trial advances.
Medical Devices & Diagnostics
Natera wins FDA Breakthrough Device status for multi-cancer blood test as NTRA climbs
Natera’s multi-cancer blood test wins FDA Breakthrough Device status after a 12-cancer review, but full performance data remain undisclosed.
Pharma & Biotech
Signatera detected 90% of recurrences versus 55% for AMERK. Is Merkel cell surveillance about to change?
Signatera showed 90% sensitivity versus 55% for AMERK in Merkel cell carcinoma, strengthening Natera’s case for broader MRD surveillance.
Medical Devices & Diagnostics
Natera just cleared a major European hurdle for Signatera, but can hospitals turn certification into adoption?
Natera’s Signatera gains European IVDR certification across multiple cancers, opening a new phase for personalized MRD testing and clinical adoption.
Pharma & Biotech
Why Natera’s latest Signatera study matters for resected metastatic colorectal cancer
Discover how Natera’s Signatera MRD test may sharpen chemotherapy decisions after colorectal liver surgery and what remains unproven.
Pharma & Biotech
Natera and Aveta Biomics bring Signatera into APG-157 Phase 3 head and neck cancer trial
See how Natera’s Signatera could sharpen APG-157’s Phase 3 evidence in head and neck cancer and what risks remain. Read the analysis.
Medical Devices & Diagnostics
Why Natera’s Diakonos Oncology collaboration matters for ctDNA-guided cancer drug development
Natera’s Signatera will track molecular response in a refractory melanoma trial. Find out why ctDNA is becoming central to oncology R&D.
Medical Devices & Diagnostics
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Medical Devices & Diagnostics
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.